Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr;27(4):616-619.
doi: 10.1038/s41591-021-01245-5. Epub 2021 Feb 22.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Matteo C Da Vià  1 , Oliver Dietrich  2 , Marietta Truger  3 , Panagiota Arampatzi  4 , Johannes Duell  1 , Anke Heidemeier  5 , Xiang Zhou  1 , Sophia Danhof  1 , Sabrina Kraus  1 , Manik Chatterjee  1 , Manja Meggendorfer  3 , Sven Twardziok  3 , Maria-Elisabeth Goebeler  1 , Max S Topp  1 , Michael Hudecek  1 , Sabrina Prommersberger  1 , Kristen Hege  6 , Shari Kaiser  6 , Viktoria Fuhr  7 , Niels Weinhold  8 , Andreas Rosenwald  7 , Florian Erhard  9 , Claudia Haferlach  3 , Hermann Einsele  1 , K Martin Kortüm  1 , Antoine-Emmanuel Saliba  2 , Leo Rasche  10   11
Affiliations
Clinical Trial

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Matteo C Da Vià et al. Nat Med. 2021 Apr.

Abstract

B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial ( NCT03361748 ) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.

PubMed Disclaimer

References

    1. Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020). - DOI
    1. Raje, N. et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019). - DOI
    1. Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019). - DOI
    1. Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267–2280 (2018). - DOI
    1. Cheng, J. et al. Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nat. Commun. 8, 1221 (2017). - DOI

Publication types

Substances

Associated data